- Posted by ISPE Boston
- On August 6, 2020
Gene editing company CRISPR Therapeutics is building a new cell therapy manufacturing facility in Framingham, Massachusetts for clinical and commercial production of the company’s investigational cell therapy product candidates.
“We look forward to building a state-of-the-art manufacturing facility, which will accelerate our programs and allow us to scale for commercial supply. We are thankful for the support from the City of Framingham and the Commonwealth of Massachusetts, and we look forward to bringing our facility online rapidly,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics. “In addition to building out this internal manufacturing capacity, we will continue to work closely with our key manufacturing partners globally.”
As the facility becomes fully operational, the company expects to hire up to approximately 100 full-time employees. The new facility is being designed to provide GMP manufacturing according FDA and EMA regulations and guidelines to support clinical supply and commercial product upon potential regulatory approval.
As reported by the Boston Globe, the company also reported that it will be moving its lab operations out of Kendall Square to a seven-story building under construction on A Street in South Boston and consolidating its offices in a 263,000 square-foot facility near the Broadway Red Line station which is set to open in 2022. (Source: CRISPR Therapeutics Website, 25 June, 2020 and The Boston Globe, 29 July, 2020)